Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development

Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.

Lightbulb
• Source: Shutterstock

Applications in oncology are moving at a more deliberate pace owing to the distinctive nature of cancer patients’ needs. Less impetus to develop novel digital outcomes measures also exists in oncology as tumor-associated outcomes rule the roost. Conversely, the toxic nature of cancer treatments, the duration of treatment, and the variety of drugs and therapeutic regimens available for the many different cancer subtypes elevates the need for objective quality of life (QoL) assessments, where wearables can play an important role.

“Wearables give us insight into patient experiences that we don’t have otherwise, because the data is so objective and dynamic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.